Company intelligence / Profile preview

Senlang Bio

Shijiazhuang, Hebei, China

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Senlang Bio is a clinical-stage biotechnology company focused on the development of innovative CAR-T cell therapies for hematological malignancies and solid tumors. Their lead product candidate, SENL101, has demonstrated significant efficacy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The company is also notable for its advancements in CD7-targeted CAR-T therapies for T-cell malignancies and is exploring multi-targeted and universal CAR-T technologies.

Therapeutic areas: OncologyHematology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Drug pipeline

38 assets

nanobody-based CD19/CD22 tandem dual CAR-T

37 more assets in the full pipeline.

Request access →

Partnerships

The Second Hospital of Hebei Medical UniversityTianjin First Central Hospital

Beyond the preview

Go deeper on Senlang Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senlang Bio.

Explore the full profile